PhaseBio Receives FDA Orphan Drug Designation for Vasomera (PB1046) for the Treatment of Cardiomyopathy Associated With Dystrophinopathies
December 01, 2015 09:00 ET
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa., Dec. 1, 2015 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company and leader in the field of biopolymer-based drugs, focused on developing...
PhaseBio Announces Initiation of Phase 2a Multiple Ascending Dose Study of Once-Weekly Basal Insulin PE0139 in Type 2 Diabetes
November 09, 2015 09:00 ET
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa., Nov. 9, 2015 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company and leader in the field of biopolymer-based drugs focused on developing...
PhaseBio to Present at Rodman & Renshaw 17th Annual Global Investment Conference
September 03, 2015 09:00 ET
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa., Sept. 3, 2015 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company and leader in the field of biopolymer-based drugs focused on developing...
PhaseBio Pharmaceuticals Announces Positive Data for Type 2 Diabetes Treatments PE0139 and PB1023
June 07, 2015 08:30 ET
|
PhaseBio Pharmaceuticals, Inc.
PE0139 was well tolerated; pharmacokinetic / pharmacodynamic profile supports once-weekly dosing
PE0139 demonstrated synergistic action with weekly GLP-1 receptor agonist PB1023
MALVERN,...
PhaseBio Pharmaceuticals to Present at the American Diabetes Association 75th Scientific Sessions
June 01, 2015 08:00 ET
|
PhaseBio Pharmaceuticals, Inc.
MALVERN, Pa., June 1, 2015 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company and leader in the field of biopolymer-based drugs focused on developing...
PhaseBio Announces Promising Pre-Clinical Results for PB1046 in Models of Duchenne Muscular Dystrophy
April 22, 2015 07:30 ET
|
PhaseBio Pharmaceuticals, Inc.
Chronic PB1046 treatment shown to ameliorate Duchenne muscular dystrophy myopathies, slow cardiac deterioration in mice
Compound protected skeletal muscle, decreased fibrosis
Data to be...
PhaseBio Raises $40 Million Series C Financing Led by AstraZeneca
March 12, 2015 07:30 ET
|
PhaseBio Pharmaceuticals, Inc.
Proceeds to enable advancement of lead drug candidates – once-weekly basal insulin and once-weekly Vasoactive Intestinal Peptide
MALVERN, Pa., March 12, 2015 (GLOBE NEWSWIRE) -- PhaseBio...
PhaseBio Announces Expansion of Leadership Team
March 03, 2015 09:00 ET
|
PhaseBio Pharmaceuticals, Inc.
Clay Thorp named Executive Chairman of the board
Jonathan P. Mow becomes Chief Executive Officer
Dr. James Ballance appointed Vice President, Research and Scientific Affairs
MALVERN,...